Aptose Biosciences Inc.

About Aptose Biosciences Inc.

Aptose Biosciences Inc. is a science-driven clinical-stage biotechnology company focused on developing precision medicines for unmet clinical needs in oncology, with an initial emphasis on hematology. Their pipeline includes small molecule cancer therapeutics designed for single agent efficacy and to enhance other anti-cancer therapies without overlapping toxicities.

Products & Services

Tuspetinib (formerly HM43239):A potent oral myeloid kinase inhibitor (MKI) targeting key kinases like SYK, FLT3, JAK, and c-KIT(mut) for the treatment of acute myeloid leukemia (AML).

Luxeptinib (Lymphoid Kinome Inhibitor - LKI):A potent non-covalent inhibitor of wildtype and mutant BTK and multiple oncogenic signaling pathways for B-cell malignancies such as CLL and NHL.

Specialties

Precision Oncology Hematology Small Molecule Cancer Therapeutics Myeloid Kinase Inhibitors Lymphoid Kinome Inhibitors

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 11900000 MR: - FA: US$11.9 million FAN: 11900000	D: 2025-09-22 FD: 2025-09-22	1 investors
2	RT: Loan T: - FT: Loan	A: 2000000 MR: - FA: US$2.0M FAN: 2000000	D: 2025-07-15 FD: 2025-07-15	1 investors
3	RT: Debt T: - FT: Debt	A: 8500000 MR: - FA: US$8.5 million FAN: 8500000	D: 2025-06-20 FD: 2025-06-20	1 investors
4	RT: Debt Conversion to Equity T: - FT: Debt Conversion to Equity	A: 1513533 MR: - FA: US$1,513,533.10 FAN: 1513533	D: 2025-03-19 FD: 2025-03-19	1 investors
5	RT: Committed Equity Facility T: - FT: Committed Equity Facility	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2025-02-13 FD: 2025-02-13	1 investors
6	RT: Public Offering T: - FT: Public Offering	A: 8000000 MR: - FA: $8 million FAN: 8000000	D: 2024-11-25 FD: 2024-11-25	3 investors
7	RT: Public Offering T: - FT: Public Offering	A: 8000000 MR: - FA: $8 million FAN: 8000000	D: 2024-11-22 FD: 2024-11-22	3 investors
8	RT: Debt T: - FT: Debt	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2024-08-30 FD: 2024-08-30	1 investors
9	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4430000 MR: - FA: $4.43 million FAN: 4430000	D: 2024-06-03 FD: 2024-06-03	-
10	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4430000 MR: - FA: $4.43 million FAN: 4430000	D: 2024-05-31 FD: 2024-05-31	1 investors
11	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 13700000 MR: - FA: approximately $13.7 million FAN: 13700000	D: 2024-01-31 FD: 2024-01-31	1 investors
12	RT: Public Offering T: - FT: Public Offering	A: 8400000 MR: - FA: US $8.4 million FAN: 8400000	D: 2024-01-26 FD: 2024-01-26	1 investors
13	RT: Private Equity T: - FT: Private Equity	A: 3000000 MR: - FA: 3 million FAN: 3000000	D: 2023-09-06 FD: 2023-09-06	1 investors
14	RT: Committed Equity Facility T: - FT: Committed Equity Facility	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2023-05-25 FD: 2023-05-25	1 investors

Debt Latest

2025-09-22

$11.9M

1 investor (Pro only)

Loan 2025-07-15

$2.0M

Debt 2025-06-20

$8.5M

View 13 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Brian Druker

M.D.

M

Michael Andreeff

Professor of Medicine

D

Daniel D. Von Hoff

Physician-in-Chief and Distinguished Professor of Translational Research

S

Stephen B. Howell

Distinguished Professor of Medicine at University of California, San Diego, and Associate Director for Clinical Research at Moores UCSD Cancer Center

W

William G. Rice

Chairman of the Board, President & Chief Executive Officer

D

Denis R. Burger

Board Member, Lead Director

View 12 more team members with Pro

Unlock Full Team Directory

Recent News